Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study

Autor: Annemarie B. van der Aart‐van der Beek, Ellen Apperloo, Niels Jongs, Dennis B. Rouw, C. David Sjöström, Iris Friedli, Lars Johansson, Daniël H. van Raalte, Klaas Hoogenberg, Hiddo J. L. Heerspink

Publikováno v: Diabetes, Obesity and Metabolism, 25(6), 1758-1768. Wiley-Blackwell
van der Aart-van der Beek, A B, Apperloo, E, Jongs, N, Rouw, D B, Sjöström, C D, Friedli, I, Johansson, L, van Raalte, D H, Hoogenberg, K & Heerspink, H J L 2023, ' Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes : A randomized cross-over clinical study ', Diabetes, Obesity and Metabolism, vol. 25, no. 6, pp. 1758-1768 . https://doi.org/10.1111/dom.15033

Aim: To evaluate the albuminuria-lowering effect of dapagliflozin, exenatide, and the combination of dapagliflozin and exenatide in patients with type 2 diabetes and microalbuminuria or macroalbuminuria. Methods: Participants with type 2 diabetes, an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d47b9e4e2d4e1801c735f6cf526e219c
https://research.vumc.nl/en/publications/8a62b75b-6a03-41ae-839a-e402962332b0

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes

Autor: Max Nieuwdorp, Richard G. IJzerman, Hiddo J.L. Heerspink, Annemarie B van der Aart-van der Beek, Daniël H. van Raalte, Klaas Hoogenberg, Charlotte C. van Ruiten

Publikováno v: Diabetes, Obesity and Metabolism, 23(8), 1851-1858. Wiley
Diabetes, obesity & metabolism, 23(8), 1851-1858. Wiley-Blackwell
Diabetes, Obesity and Metabolism, 23(8), 1851-1858. Wiley-Blackwell
van Ruiten, C C, van der Aart-van der Beek, A B, IJzerman, R G, Nieuwdorp, M, Hoogenberg, K, van Raalte, D H & Heerspink, H J L 2021, ' Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial ', Diabetes, Obesity and Metabolism, vol. 23, no. 8, pp. 1851-1858 . https://doi.org/10.1111/dom.14410
Diabetes, Obesity & Metabolism

Aims: To evaluate the effects of separate and combined use of the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin and the glucagon-like peptide-1 receptor agonist (GLP-1RA) exenatide on measures of kidney function. Methods: In this pre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db634e9eacb798bab746cd9b0bbe03a3
https://research.rug.nl/en/publications/59bdca93-36c4-452f-9139-f7df36899868

Kidney and heart failure outcomes associated with SGLT2 inhibitor use

Autor: Annemarie B, van der Aart-van der Beek, Rudolf A, de Boer, Hiddo J L, Heerspink

Publikováno v: Nature reviews. Nephrology. 18(5)

Chronic kidney disease (CKD) and heart failure affect many people worldwide. Despite the availability of pharmacological treatments, both diseases remain associated with considerable morbidity and mortality. After observations that sodium-glucose co-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::184317b5272ee17c3918dca784759524
https://pubmed.ncbi.nlm.nih.gov/35145275

Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials

Autor: Peter J. Greasley, Klaas Hoogenberg, Daniel Reyner, Daniël H. van Raalte, Gozewijn D. Laverman, Annemarie B van der Aart-van der Beek, Qiang Li, David Z.I. Cherney, Gian Luca Di Tanna, Hiddo J.L. Heerspink, Bergur V. Stefánsson

Publikováno v: Diabetes, Obesity and Metabolism, 23(8), 1961-1967. Wiley-Blackwell
Diabetes, Obesity and Metabolism, 23(8), 1961-1967. Wiley
van der Aart-van der Beek, A B, Cherney, D, Laverman, G D, Stefansson, B, van Raalte, D H, Hoogenberg, K, Reyner, D, Li, Q, di Tanna, G L, Greasley, P J & Heerspink, H J L 2021, ' Renal haemodynamic response to sodium-glucose cotransporter-2 inhibition does not depend on protein intake: An analysis of three randomized controlled trials ', Diabetes, Obesity and Metabolism, vol. 23, no. 8, pp. 1961-1967 . https://doi.org/10.1111/dom.14411
Diabetes, Obesity & Metabolism

High protein intake may increase intraglomerular pressure through dilation of the afferent arteriole. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce intraglomerular pressure through activation of tubuloglomerular feedback. Given these o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36bc9c59f000ef4dc5f77b5d21490ef5
https://pubmed.ncbi.nlm.nih.gov/34387935

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

Autor: Ron T. Gansevoort, Qiang Li, Peter J. Greasley, Heather N. Reich, Abdul Halim Abdul Gafor, Annemarie B. van der Aart-van der Beek, Gozewijn D. Laverman, Sunita K. Singh, David Z.I. Cherney, Daniel C. Cattran, David W. Boulton, Hiddo J.L. Heerspink, Jasper Stevens, Soo Kun Lim, Jeroen V. Koomen, Claire C J Dekkers, Marc G. Vervloet, Sean J. Barbour

Publikováno v: Clinical Pharmacokinetics, 60(4), 517-525. Adis International Ltd
Clinical Pharmacokinetics. Springer International Publishing AG
van der Aart-van der Beek, A B, Koomen, J V, Dekkers, C C J, Barbour, S J, Boulton, D W, Gansevoort, R T, Greasley, P J, Abdul Gafor, A H, Laverman, G D, Li, Q, Lim, S K, Stevens, J, Vervloet, M G, Singh, S, Cattran, D C, Reich, H N, Cherney, D Z I & Heerspink, H J L 2021, ' Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease ', Clinical Pharmacokinetics, vol. 60, no. 4, pp. 517-525 . https://doi.org/10.1007/s40262-020-00956-1
Clinical Pharmacokinetics

Background and Objective: Dapagliflozin, a sodium-glucose co-transporter inhibitor, was originally developed as an oral glucose-lowering drug for the treatment of type 2 diabetes mellitus. Emerging data suggest that cardiovascular and kidney benefits

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0019ef2d4e248ec262e811dc82327340
https://research.vumc.nl/en/publications/9c638d94-b92b-4158-9794-ffb423cd4860